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ORIGINAL ARTICLE
Introduction: Tumor-associated macrophages (TAMs) are divided 
into M1 and M2 macrophages. M1 macrophages inhibit tumor 
growth, whereas M2 macrophages promote tumor growth and 
metastasis. The aim of this study was to examine the possible causes 
leading to the formation of an M2-macrophage–dominant tumor 
microenvironment in non–small-cell lung cancer.
Methods: Forty-eight archived lung tumor samples were exam-
ined for the expression of interleukin-17 (IL-17) receptors, IL-17 
receptor A (IL-17RA) and IL-17 receptor C (IL-17RC), and the 
number of TAMs using immunohistochemical staining. Twenty 
fresh lung tumors and matched normal lung tissues were examined 
for expression of IL-17, cyclooxygenase-2, and prostaglandin E2 
(PGE2), using enzyme-linked immunosorbent assay and Western 
blot analysis. Macrophage-migration assays were performed using 
fresh lung tumor tissues and IL-17 as chemoattractants. Induction of 
M2-macrophage differentiation was analyzed using real-time quanti-
tative polymerase chain reaction.
Results: TAMs expressed IL-17RA and IL-17RC. Lung tumors 
expressed higher levels of IL-17, cyclooxygenase-2, and PGE2, 
compared with normal lung tissues. Lung tumor tissues attracted 
migration of mouse RAW264.7 macrophages and primary peritoneal 
macrophages through IL-17, which was mediated by IL-17RA and 
IL-17RC. IL-17 did not induce either M1- or M2-macrophage differ-
entiation. However, human lung cancer A549 cells strongly induced 
M2-macrophage differentiation of RAW264.7 macrophages when 
the two cell lines were cocultured. The inductive factor secreted by 
A549 cells was identified to be PGE2.
Conclusions: IL-17 recruits macrophages, and PGE2 induces 
M2-macrophage differentiation, hence the increased levels of 
IL-17 and PGE2 in lung cancer contribute to the formation of an 
M2-macrophage–dominant tumor microenvironment.
Key Words: COX-2, IL-17, PGE2, Macrophage, Tumor micro- 
environment.
(J Thorac Oncol. 2012;7:1091–1100)
Lung cancer is the most common cause of cancer-related death worldwide. The American Cancer Society estimated 
that there were approximately 221,130 new cases and 156,940 
deaths caused by lung cancer in the United States in 2011. 
Lung cancer is the second-most common malignancy and the 
most common cause of cancer-related death in both American 
men and women.1 In China, the total estimated new lung can-
cer cases and deaths were 536, 407 and 475,768, respectively, 
in 2005.2
Tumor microenvironment plays an important role in 
lung cancer growth and metastasis. Tumor microenvironment 
includes tumor cells, fibroblasts, endothelial cells, macrophages, 
dendritic cells, and lymphocytes, as well as products of these 
cells such as extracellular matrix, cytokines, chemokines, growth 
factors, enzymes, and cellular metabolites.3 Macrophages are 
critical in influencing tumor growth, angiogenesis, invasion, 
and metastasis as they express growth factors, cytokines, 
chemokines, and enzymes.4 The tumor-associated macrophages 
(TAMs) are composed of heterogeneous populations with a 
spectrum of diverse biological properties.5 TAMs at the two 
ends of the spectrum are called M1 and M2 macrophages, 
respectively, mirroring the T
H
-1 and T
H
-2 nomenclature of 
T helper cells.5 Interferon-γ (IFN-γ), lipopolysaccharides, 
tumor necrosis factor α (TNFα), and granulocyte–monocyte 
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colony-stimulating factor are known to induce  differentiation 
of monocytes into M1 macrophages. M1 macrophages express 
high levels of inducible nitric oxide synthase (iNOS), TNFα, 
interleukin (IL)-1β, IL-6, IL-12, IL-18, IL-23, CXC ligand 10, 
human leukocyte antigen D-region R protein group, and reactive 
oxygen and nitrogen intermediates.5–9 IL-4, IL-10, IL-13, 
IL-21, activin A, immune complexes, and glucocorticoids 
induce monocyte differentiation into M2 macrophages.5 M2 
macrophages express high levels of arginase I, IL-1 receptor 
antagonist (IL-1ra), IL-10, CC ligand 22, mannose receptor, 
galactose receptor, and CD163 antigen.5,10 It is believed that 
M1 macrophages inhibit tumor growth by producing effector 
molecules such as reactive oxygen intermediates, reactive 
nitrogen intermediates, and TNFα, whereas M2 macrophages 
promote tumor growth and metastasis by secretion of 
growth factors, vascular endothelial growth factor, matrix 
metalloproteinases, and immunosuppressive cytokines/
chemokines.6 The balance between the M1 and M2 forms of 
macrophages determines the net anti- or protumor effects of 
the TAM population.11
We have previously reported that the number of TAMs 
in the tumor islets is positively associated with survival time, 
whereas the number of TAMs in the tumor stroma is negatively 
associated with survival time in patients with non–small-cell 
lung cancer (NSCLC).12 Approximately 70% of TAMs are 
M2 macrophages and the remaining 30% are M1 macro-
phages in NSCLC.13 It is not clear why there are more M2 
macrophages than M1 macrophages in the lung tumor micro-
environment. In this study, we found that lung tumor tissues 
expressed significantly higher levels of IL-17 and prostaglan-
din E2 (PGE2) than normal lung tissues; IL-17 served as a 
chemoattractant to recruit macrophages into the lung tumors; 
and, PGE2 induced differentiation of M2 macrophages. These 
findings suggest that IL-17 and PGE2 are involved in creat-
ing an M2-macrophage–dominant tumor microenvironment 
in NSCLC.
MATERIALS AND METHODS
Human Tissue Samples
The collection and use of human tissue samples were 
approved by the Institutional Review Board of West China 
Hospital, Sichuan University. The procedures were in accor-
dance with the Ethical Principles for Medical Research 
Involving Human Subjects as formulated in the World 
Medical Association Declaration of Helsinki (revised in 
2008). Forty-eight lung tumor specimens were obtained from 
the archives of formalin-fixed, paraffin-embedded tissue 
blocks in the Department of Thoracic Surgery, West China 
Hospital, Sichuan University. The tissues were collected from 
surgeries performed from August 1999 to August 2001. The 
patients were followed up until December 2007, through out-
patient visits and/or correspondence with family members. In 
addition, 20 fresh lung tumor samples and matched normal 
lung tissues were collected and used from December 2010 to 
June 2011. The normal lung tissues were sampled approxi-
mately 5 cm away from the edge of the lung tumors. Both 
the lung tumors and normal lung tissues were confirmed by 
pathological examination. Histological evaluation was based 
on World Health Organization criteria.14 Tumor stage was 
evaluated according to the International Union against Cancer 
TNM classification system.15 Tumor-grading criteria were 
published previously.12 The clinicopathological characteristics 
are summarized in Table 1. All lung cancer patients undergo-
ing operation during the sampling period were included. The 
exclusion criteria were metastatic cancers, small-cell cancers, 
chemotherapy or radiotherapy before surgery, and absence of 
follow-up (except the fresh samples). For the 20 pairs of fresh 
lung tumors and normal lung samples no follow-up data were 
available at the time of this report.
Immunohistochemical Staining
Immunohistochemical staining was performed as 
described previously.12 Rabbit anti–IL-17 receptor C (IL-17RC) 
intracellular domain antibodies have been described previ-
ously.16,17 Rabbit anti–IL-17 receptor A (IL-17RA) antibodies 
were purchased from Beijing Biosynthesis Biotechnology Co. 
(Beijing, China). Mouse anti-human CD68 monoclonal antibod-
ies (clone KP1) were obtained from Zhongshan Goldenbridge 
Biotechnology Co. (Beijing, China). The tissue sections were 
stained with anti–IL-17RC (or anti–IL-17RA) and/or anti-
CD68 antibodies, using the DouSP double-stain kit (Maxim-
Bio, Fuzhou City, China). Nonimmune rabbit serum or mouse 
isotype IgG1 served as negative control. Development of red 
color was performed using streptavidin-peroxidase conjugate 
and 3-amino-9-ethylcarbazole. Development of black-purple 
color was performed using streptavidin-alkaline-phosphatase 
conjugate and 5- bromo-4-chloro-3-indolyl phosphate/nitro 
blue tetrazolium. Five representative high-power fields (× 400 
TABLE 1.  Clinicopathological Characteristics of Patients with 
Non–Small-Cell Lung Cancer
Variable
Archived Samples Fresh Samples
N = 48
5 yrs  
Survival (%) N = 20
Age, yrs median (range) 62 (37–80) Overall = 33 58 (45–77)
Sex (male: female) 39: 9 14:6
Tumor stage
 I 16 50 7
 II 9 22 3
 III 18 27 9
 IV 5 20 1
Histology
 Adenocarcinoma 19 21 10
 Squamous cell carcinoma 29 41 10
Tumor grade
 Well differentiation 1 N/C* 0
 Moderate differentiation 26 42 9
 Poor differentiation 15 26 11
 Not recorded 6 16 0
Lymph node metastasis
 No 31 45 10
 Yes 17 11 10
*This patient lived for 4.5 yrs after surgery.
N/C, not calculated.
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magnification; area equals 0.44 mm2 per field) of tumor islets 
or stroma per tissue section were randomly selected using an 
Olympus BX51 microscope (Olympus, Tokyo, Japan). Tumor 
islet is a region in a tumor tissue section that contains a solid 
sheet of tumor cells side by side in a continuous manner (i.e., a 
nest of tumor cells; also named tumor nest), giving an appear-
ance of “island” extending into the “sea” (i.e., the stroma). 
Tumor stroma is the space between individual sheets of tumor 
cells, which is often filled with fibroblasts and other types of 
cells. The number of macrophages that were double stained 
positive for IL-17RC and CD68 was counted by two investiga-
tors who were blinded in regard to the clinicopathological data. 
Macrophage density of each case was an average of the five 
high-power fields.
Measurement of IL-17 and PGE2 Levels
Approximately 200 mg of fresh lung tumor or normal 
lung tissue was put into a Dounce homogenizer with 200 
μl of radioimmunoprecipitation assay lysis buffer. After 
homogenization on ice, the protein extract was centrifuged at 
14,000 g for 10 minutes at 4°C. The supernatant was stored 
at −80°C until measurement. To obtain conditioned media from 
cultured cell lines, human lung cancer cell lines (SPC-A-1, 
YTMLC-90, and A549), and mouse Lewis lung carcinoma cell 
line (LLC1) were cultured in serum-free Dulbecco’s Modified 
Eagle Medium (DMEM) for 24 hours. The conditioned media 
were centrifuged at 14,000 g for 10 minutes at 4°C and the 
supernatants were stored at −80°C until usage. IL-17 levels 
in the tissue protein extracts were measured using a human 
IL-17 enzyme-linked immunosorbent assay kit (Wuhan 
Boster Biological Technology, Wuhan, China) according to 
the manufacturer’s instructions. PGE2 levels in the tissue 
protein extracts and conditioned media were measured using 
a human PGE2 kit (Uscn Life Science Inc., Wuhan, China) 
according to the manufacturer’s instructions.
Isolation of Mouse Peritoneal Macrophages
Animal protocol was approved by the Institutional 
Animal Care and Use Committee of Tulane University. 
IL-17RA knockout (KO) mice (C57BL/6 background) were 
provided by Amgen Inc. (Seattle, WA).18 IL-17RC KO mice 
were generated in Dr. You’s laboratory at Tulane University 
using C57BL/6-derived embryonic stem (ES) cells purchased 
from the Texas Institute for Genomic Medicine (Houston, TX). 
A Bgeo trap sequence was inserted immediately upstream to 
the start codon of Il17rc gene to abolish Il17rc expression in 
the ES cells. The ES cells were injected into C57BL/6 albino-
mouse blastocysts. The resulting male chimeras were crossed 
with C57BL/6 females to generate mice heterozygous for the 
IL-17RC mutation (Il17rc+/−), which were subsequently inter-
crossed to generate IL-17RC KO mice (Il17rc−/−). Genotypes 
were confirmed by polymerase chain reaction (PCR) using 
mouse-tail DNA. About 1 ml of sterile 4% thioglycolate 
broth was injected into C57BL/6 wild-type, IL-17RA KO, 
and IL-17RC KO mouse peritoneal cavities. Four days later, 
the mice were humanely killed and 5 ml phosphate-buffered 
saline was injected into the peritoneal cavities to collect the 
peritoneal macrophages as described.19
Cell Migration Assays
Transwell (Boyden chamber) assays were performed to 
examine the migration of mouse RAW264.7 macrophages and 
peritoneal macrophages induced by tissues or recombinant 
mouse IL-17 (R&D Systems, Inc., Minneapolis, MN). 
Approximately 100-mg lung tumor or normal lung tissues 
were minced into 1-mm pieces and washed three times with 
phosphate-buffered saline. Each sample was split equally 
into five lower chambers with 600-μl serum-free DMEM and 
cultured for 16 hours in a 37°C, 5% CO
2
 humidified incubator. 
Then, 20,000 RAW264.7 cells in 200 μl serum-free DMEM 
were plated into each upper chamber for 2 hours. The cells that 
migrated through the inserts were stained with 0.5% crystal 
violet and counted. To test if IL-17 in the tumor tissues was 
inducing macrophage migration, 5 μg/ml of mouse isotype 
control IgG or mouse anti–IL-17 neutralizing antibodies 
(R&D Systems) were added into the lower chamber 1 hour 
before addition of RAW264.7 cells in the upper chamber. 
Similarly, 0.01 or 1 ng/ml rmIL-17 was added to serum-free 
DMEM in the lower chamber; 20,000 RAW264.7 cells or 
mouse peritoneal macrophages were loaded into the upper 
chamber for 2 hours and then the migrated cells were counted.
Macrophage Differentiation
RAW264.7 cells were treated without or with 50 ng/ml 
of recombinant mouse IL-4, interferon-γ, and/or IL-17 for 3 
hours. Real-time PCR was performed to determine the mRNA 
levels of M1-macrophage markers (iNOS, TNFα, and IL-18) 
and M2-macrophage markers (arginase I, IL-10, and IL-1ra) 
as described.17 In separate experiments, RAW264.7 cells were 
treated without or with 10, 100, and 500 nM of PGE2 (Sigma-
Aldrich, St. Louis, MO) for 3 hours, or with conditioned 
medium for 24 hours; then, real-time PCR was performed. 
One million RAW264.7 cells were mixed and cocultured with 
1 million lymph node metastasis of cancer of prostate (LNCaP) 
(human prostate cancer cell line) or A549 cells in serum-free 
medium for 24 hours, and real-time PCR was performed using 
the mouse-specific PCR primers (see sequences in Table 2), thus 
the human mRNAs from LNCaP and A549 cells in the cocul-
ture system did not interfere with the real-time PCR analysis.
Western Blot
Protein extracts from lung tumors or normal lung tis-
sues were analyzed with Western blot to determine levels 
of cyclooxygenase-2 (COX-2) and β-actin as described.17 
The integrated density values of the protein bands were ana-
lyzed with Quantity One software (Version 4.6.5; Bio-Rad 
Laboratories, Hercules, CA). The ratios of COX-2/β-actin 
between lung tumors and normal lung tissues were compared. 
RAW264.7 cells were treated with control medium or con-
ditioned medium from A549 cells, and arginase I expression 
was determined by Western blot.
Characterization of Cell Lines
Human lung carcinoma cell line (A549), human pros-
tate cancer cell line (LNCaP), mouse LLC1, and mouse 
RAW264.7 were obtained from the American Type Culture 
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Collection (Manassas, VA) from 2003 to 2010. These cell 
lines were frozen in liquid nitrogen within 1 month after 
receipt and were cultured for less than 6 months after resusci-
tation from frozen status. The methods of characterization can 
be found online at http://www.atcc.org. Human lung adeno-
carcinoma cell line SPC-A-1 and human lung squamous cell 
carcinoma cell line YTMLC-90 were originally characterized 
and reported in Chinese journals.20,21 The two lung cancer cell 
lines were used widely by Chinese investigators.22,23
Statistical Analysis
Statistical analysis was carried out using the Statistical 
Package for the Social Sciences (SPSS, version 13.0; SPSS 
Inc., Chicago, IL). For the 48 archived samples, the median 
number of macrophages was used as a cutoff point to dichot-
omize the data. The Kaplan–Meier survival curves were 
used to look for correlation between the macrophage num-
ber and patient’s survival time, or between the ratio of cells 
in the tumor islets versus stroma and patient’s survival time. 
Statistical significance was analyzed using the log-rank test. 
Data from the 20 fresh lung tumors and matched normal lung 
tissues were analyzed using paired Student’s t test. Student’s t 
test was used to analyze the remaining data. P values less than 
0.05 were considered statistically significant.
RESULTS
TAMs in Human Lung Cancer Express IL-17RC 
and IL-17RA
To investigate if human lung tumors express IL-17RC, 
immunohistochemical staining of IL-17RC was performed. 
Red blood cells and inflammatory cells were seen in the 
tumor sections, including macrophages with hemosiderin 
deposits within the cells (Fig. 1A). IL-17RC expression was 
not detectable in the tumor cells; however, macrophage-like 
cells were stained strongly positive for IL-17RC (Fig. 1B). To 
confirm that the IL-17RC–positive cells were macrophages, 
the tissue sections were double stained for IL-17RC (dark-
purple) and macrophage marker CD68 (red). Indeed, the 
IL-17RC–positive cells were also stained positive for CD68 
(Fig. 1C). Because IL-17RA is ubiquitously expressed in 
many cell types,24 the tumor sections were also double stained 
for IL-17RA and CD68. We found that CD68-positive mac-
rophages and the tumor cells expressed IL-17RA (Fig. 1D).
The Number of Macrophages is Associated 
with Patient’s Survival
We counted the number of IL-17RC/CD68 double-
positive macrophages in the tumor islets and stroma. The median 
number of macrophages was 23.4/mm2 (range, 2.3–168.9/
mm2) in the tumor islets and 25.7/mm2 (range, 2.3–102.3/mm2) 
in the tumor stroma. The median ratio of macrophage number 
in the tumor islets divided by macrophage number in the tumor 
stroma was 0.9 (range, 0.6–2.1). We found that the patients 
with above-the-median macrophage number in the tumor islets 
had a significantly better cumulative survival compared with 
the patients with below-the-median macrophage number in the 
tumor islets (p = 0.034, Fig. 1E). In contrast, the patients with 
above-the-median macrophage number in the tumor stroma 
had a significantly worse cumulative survival compared with 
the patients with below-the-median macrophage number 
in the tumor stroma (p = 0.042, Fig.1F). When the ratio 
of the macrophage number in the tumor islets versus ratio of 
the macrophage number in the tumor stroma was compared, 
the patients with above-the-median ratio (islets/stroma) had 
a significantly better cumulative survival compared with the 
patients with below-the-median ratio (p = 0.000, Fig. 1G). 
These findings are consistent with our previous results.12
Lung Tumors Recruit Macrophages by 
Expressing High Levels of IL-17
Because TAMs expressed both IL-17RA and IL-17RC 
receptors, we examined whether IL-17 cytokine was also pres-
ent in the lung tumors. We found that the mean IL-17 level 
was 25.3 pg/mg protein (95% confidence interval: 23.4–27.2 
pg/mg protein) in normal lung tissues and 37.2 pg/mg pro-
tein (95% confidence interval: 33.9–40.5 pg/mg protein) in 
lung tumors. The IL-17 level in lung tumors increased by 47% 
compared with that in normal lung tissues, which was statis-
tically significant (p = 0.010, Fig. 2A). It has been reported 
that IL-17 can recruit neutrophils into the rat airways,25 so we 
tested whether lung tumors could attract migration of macro-
phages. We found that lung tumor tissues in ex vivo culture 
significantly stimulated migration of mouse RAW264.7 mac-
rophages compared with normal lung tissues and serum-free 
medium (p = 0.023 or 0.017, Fig. 2B). The effects of lung tumor 
tissues on macrophage migration were inhibited by neutral-
izing IL-17 with anti–IL-17 antibodies (Fig. 2C). To further 
TABLE 2.  Primer Sequences for Real-Time PCR
Name Forward Reverse Product (bp)
Gapdh TaqMan Rodent GAPDH Control Reagents (#4308313) (from Applied Biosystems, Foster 
City, CA) sequences are proprietary, spanning exons 2 and 3
177
Nos2 (iNOS) CAGCTGGGCTGTACAAACCTT CATTGGAAGTGAAGCGTTTCG 95
Il18 GACTCTTGCGTCAACTTCAAGG CAGGCTGTCTTTTGTCAACGA 169
Tnf (TNFα) CTACTCCCAGGTTCTCTTCAA GCAGAGAGGAGGTTGACTTTC 111
Arg1 TGGCTTGCGAGACGTAGAC GCTCAGGTGAATCGGCCTTTT 160
Il10 CTGGACAACATACTGCTAACCG GGGCATCACTTCTACCAGGTAA 108
Ilrn (Il-1ra) AAATCTGCTGGGGACCCTAC TGAGCTGGTTGTTTCTCAGG 164
PCR, polymerase chain reaction; bp, base pair; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; iNOS, inducible nitric oxide synthase; TNFα, tumor necrosis factor α; 
IL-1ra, interleukin-1 receptor antagonist.
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test whether IL-17 is responsible for macrophage migration, 
recombinant mouse IL-17 was used instead of the lung tumor 
tissues in the migration assays. We found that IL-17 dose-
dependently induced migration of RAW264.7 macrophages 
(Fig. 2D). Furthermore, we found that IL-17 induced migra-
tion of mouse peritoneal macrophages that were isolated from 
wild-type mice, but IL-17 failed to induce migration of mouse 
peritoneal macrophages that were isolated from IL-17RA KO 
or IL-17RC KO mice (Fig. 2E).
Lung Cancer Cells Induce M2-Macrophage 
Differentiation
To test whether IL-17 can affect macrophage 
differentiation besides macrophage recruitment, we treated 
FIGURE 1. Tumor-associated macrophages expressed IL-17RC and IL-17RA. A, H&E staining of lung adenocarcinoma; open 
arrows, adenocarcinoma cells; arrows, macrophages with hemosiderin deposits; arrowheads, red blood cells. B, IHC of IL-17RC; 
open arrows, adenocarcinoma cells; arrows, macrophages. C, Double staining of IL-17RC (dark purple ) and CD68 (red); open 
arrows, adenocarcinoma cells; arrows, macrophages; square boxes indicate macrophages in the tumor stroma and a circle 
indicates macrophages in the tumor islet. D, Double staining of CD68 (dark purple) and IL-17RA (red); open arrow, adenocarci-
noma cells; arrows, macrophages; square boxes indicate macrophages in the tumor stroma and a circle indicates macrophages 
in the tumor islet. Original magnifications, 200× for photomicrographs and 400× for inserts. E–G, Kaplan–Meier survival curves 
demonstrate the number or ratio of macrophages in correlation to patient’s survival. Macrophage number represents an aver-
age number of IL-17RC/CD68 double stained cells in five high-power fields of each tumor specimen; a total of 48 specimens 
were separated into two groups by the median value, with one group having macrophage number or the ratio > median value 
and another group having macrophage number or the ratio < median value; statistical significance was analyzed using the 
log-rank test. The median number of macrophages was 23.4/mm2 in the tumor islets and 25.7/mm2 in the tumor stroma. The 
median ratio of macrophage number in the tumor islets divided by macrophage number in the tumor stroma was 0.9. IL-17RC, 
interleukin-17 receptor C; IL-17RA, interleukin-17 receptor A; H&E, hematoxylin and eosin; IHC, immunohistochemical.
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RAW264.7 macrophages with IL-4, interferon (INF)-γ, 
and/or IL-17, as it has been shown that IL-4 and INF-γ 
play opposing roles in macrophage differentiation.26 We 
found that IL-4 induced expression of arginase I and IL-10 
(markers of M2 macrophages), whereas INF-γ induced 
expression of iNOS (a marker of M1 macrophages) (Fig. 
3A). In contrast, IL-17 did not induce any of the M1- or 
M2-macrophage markers (Fig. 3A). When IL-17 was 
combined with either IL-4 or INF-γ, IL-17 did not enhance 
the effects of IL-4 or INF-γ (Fig. 3B). To mimic macrophage 
differentiation after being recruited into the lung tumors, 
RAW264.7 macrophages were cocultured with human lung 
cancer A549 cells and human prostate cancer LNCaP cells. 
We found that coculture with A549 cells dramatically and 
significantly induced expression of arginase I and IL-10 by 
4000- to 6000-fold in RAW264.7 macrophages, compared 
with coculture with LNCaP cells (Fig. 3C). Expression of 
IL-1ra, iNOS, IL-18, and TNFα was only slightly induced by 
two- to sixfold (Fig. 3D). To test if any factors were secreted 
by A549 cells to induce M2-macrophage differentiation, 
the conditioned medium of A549 cells was used to treat 
RAW264.7 macrophages. We found that mRNA expression 
of arginase I and IL-10 was induced by the conditioned 
medium but not the control medium (Fig. 3E). In addition, 
when the conditioned medium was boiled for 10 minutes 
to denature any protein products, the boiled conditioned 
medium induced more arginase I and IL-10, compared with 
the conditioned medium (Fig. 3E). Furthermore, arginase I 
protein expression was also increased by 24-hour treatment 
with the conditioned medium, particularly the boiled 
conditioned medium (Fig. 3F).
Lung Tumors Synthesize PGE2 to Induce  
M2-Macrophage Differentiation
To investigate which factors are responsible for the 
induction of arginase I expression, we searched the literature 
reports on proteins and metabolites that are produced by 
A549 cells. Because boiling did not impair the ability of 
the conditioned medium to induce arginase I, we speculated 
that the factor(s) must be heat-stable, thus ruling out all 
protein products such as chemokines/cytokines. It has been 
reported that PGE2, a heat-stable metabolite of arachidonic 
acid, can induce arginase activity in murine bone-marrow–
derived macrophages,27 and that murine Lewis lung 
carcinoma cells can produce PGE2 to induce arginase 
I expression in myeloid suppressor cells and peritoneal 
macrophages.28 Therefore, we measured PGE2 levels in the 
conditioned media from human and mouse lung cancer cell 
FIGURE 2. Lung tumors recruited macrophages through expressing high levels of IL-17. A, IL-17 levels in 20 lung tumors 
and matched normal lung tissues. B, Migration of RAW264.7 macrophages in Transwell assays; RAW264.7 macrophages were 
plated in the upper chamber and human tissues were placed in the lower chamber; results represent averages and SEs (error 
bars) from 12 pairs of tissue samples. C, Migration of RAW264.7 macrophages in Transwell assays; 5 μg/ml of mouse control 
IgG or anti-IL-17 neutralizing antibodies were added into the lower chamber 1 hr before plating RAW264.7 macrophages in 
the upper chamber; results were from five pairs of tissue samples. D, Migration of RAW264.7 macrophages in Transwell assays; 
recombinant mouse IL-17 was added in the lower chamber; results were from five independent experiments. E, Migration of 
mouse peritoneal macrophages in Transwell assays; IL-17 was added in the lower chamber; results were representatives of three 
independent experiments. IL-17, interleukin-17.
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lines. We found that human lung cancer cell lines (SPC-
A-1, YTMLC-90, and A549) and murine LLC1 secreted 
PGE2 (Fig. 4A). We found that PGE2 dose-dependently 
induced arginase I and IL-10 expression in RAW264.7 
macrophages (Fig. 4B). To determine whether human lung 
tumors secrete PGE2, we measured PGE2 levels in 20 fresh 
lung tumor tissues. We found that human lung tumors had 
significantly higher levels of PGE2 compared with normal 
lung tissues (p = 0.013, Fig. 4C). Because COX-2 is a 
key enzyme in the biosynthesis of prostaglandin H2 and 
subsequently PGE2, we measured COX-2 levels in 20 lung 
tumors. We found that lung tumors expressed significantly 
higher levels of COX-2 compared with normal lung tissues 
(Fig. 4D and 4E).
DISCUSSION
The present study shows that TAMs in lung tumors 
express IL-17RC and IL-17RA, suggesting that macrophages 
may respond to IL-17 stimuli. Because IL-17RC staining 
alone or in combination with CD68 staining clearly identi-
fies TAMs, IL-17RC seems to be a promising new marker for 
TAMs. Indeed, when we used IL-17RC/CD68 double staining 
to count the number of TAMs, we showed that the number of 
TAMs was correlated with patient’s survival. This finding is 
consistent with our previous study, in which CD68 staining 
alone was used to detect TAMs.12 In both studies, we found that 
the number of TAMs in the tumor islets is positively associated 
with prognosis, whereas the number of TAMs in the tumor 
stroma is negatively associated with prognosis. We speculate 
FIGURE 3. Lung cancer cells induced M2-macrophage differentiation. A–E, real-time polymerase chain reaction analysis of 
mRNA expression in RAW264.7 macrophages. A and B, RAW264.7 macrophages were treated without or with 50 ng/ml of 
IL-4, INF-γ, and/or IL-17 for 3 hrs. C and D, RAW264.7 macrophages were cocultured with A549 or LNCaP cells for 24 hrs. 
E, RAW264.7 macrophages were treated with the Dulbecco’s Modified Eagle Medium, conditioned medium from A549 cells 
(conditioned medium [CM]), boiled medium, or boiled CM for 24 hrs. F, Western blot analysis of arginase I expression in 
RAW264.7 macrophages treated with medium, boiled medium, CM, or boiled CM. mRNA, messenger ribonucleic acid; IL-17, 
interleukin-17.
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that this phenomenon is caused by a higher percentage of M2 
macrophages in the tumor stroma than in the tumor islets. 
We have recently reported that approximately 70% to 85% of 
TAMs in the tumor stroma are M2 macrophages, whereas the 
percentages of M2 macrophages in the tumor islets vary from 
approximately 53% in the 5-year survival group to 94% in the 
FIGURE 4.  Lung tumors synthesized PGE2 to induce M2-macrophage differentiation. A, PGE2 concentrations in the conditioned 
media from lung cancer cell lines; 1 × 105 cells were cultured in 5 ml of serum-free Dulbecco’s Modified Eagle Medium for 24 hrs, 
and PGE2 levels in the media were determined by ELISA. B, Real-time polymerase chain reaction analysis of mRNA expression in 
RAW264.7 macrophages treated without or with PGE2 for 3 hrs. C, PGE2 levels in 20 lung tumors and matched normal lung tis-
sues were measured by ELISA. D, Western blot analysis of COX-2 expression in 20 lung tumors and matched normal lung tissues; 
β-actin was probed to normalize the amounts of loaded proteins; four representative pairs are shown; N, normal lung tissue; T, 
lung tumor. E, Relative COX-2 levels are shown as ratios of COX-2/β-actin calculated by imaging analysis of protein bands on 
Western blots. F, Schematic summary of macrophage recruitment and differentiation in lung cancer. TH-17 cells in lung tumors 
secrete IL-17 that recruits monocytes/macrophages into the tumor microenvironment; lung cancer cells express COX-2 and 
secrete PGE2; then, PGE2 and other cytokines (e.g., IL-4, IL-10, IL-13, and IL-21) induce monocytes/macrophages to differentiate 
into M2 macrophages that express IL-1ra, IL-10 and arginase I. Interferon-γ, lipopolysaccharides, granulocyte–monocyte colony-
stimulating factor, and TNFα induce monocytes/macrophages to differentiate into M1 macrophages that express inducible nitric 
oxide synthase, IL-18 and TNFα. M1 macrophages inhibit tumor growth, whereas M2 macrophages promote tumor growth and 
metastasis by secretion of growth factors, vascular endothelial growth factors and matrix metalloproteinases. In lung cancer, the 
signals that induce M2-macrophage differentiation are more powerful than the signals that induce M1-macrophage differentia-
tion, resulting in more M2 macrophages than M1 macrophages in the lung tumor microenvironment. PGE2, prostaglandin E2; 
ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction; mRNA, messenger ribonucleic acid; IL-17, interleu-
kin-17; COX-2, cyclooxygenase-2; TNFα, tumor necrosis factor α; IL-1ra, interleukin-1 receptor antagonist.
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1-year survival group.13 Because M2 macrophages promote 
tumor growth and metastasis, more M2 macrophages seem to 
correlate with poorer prognosis. It is worth pointing out that 
IL-17RC staining is unlikely to distinguish between M1 and 
M2 macrophages, as IL-17RC is coexpressed with CD68 in 
all TAMs.
Our data demonstrate that IL-17 is a chemoattractant for 
RAW264.7 macrophages and mouse peritoneal macrophages. 
IL-17’s chemotactic function is mediated through IL-17RA 
and IL-17RC because KO of either receptor completely abol-
ishes macrophage migration induced by IL-17. This is con-
sistent with the literature report that a receptor heterodimer 
is preferred by IL-17 cytokines29; thus, either IL-17RA KO 
or IL-17RC KO abolishes IL-17 signaling.18,30 IL-17–induced 
macrophage migration is not because of increased chemoki-
nesis, as macrophage migration was not increased when IL-17 
was added to both the upper and lower chambers at the same 
concentration (data not shown). Because lung tumors express 
higher levels of IL-17 compared with normal lung tissues, we 
speculate that monocytes/macrophages may be recruited into 
the tumor microenvironment by IL-17. The source of IL-17 
is likely to be the IL-17–secreting T helper cells (T
H
-17 cells) 
in the tumor tissues rather than the tumor cells per se, as we 
did not detect any IL-17 protein secreted by the four lung can-
cer cell lines studied (data not shown), and other investiga-
tors found no IL-17 mRNA or protein expression in Sq-19 
and A549 lung cancer cell lines.31 Our data show that lung 
tumor tissues can attract migration of RAW264.7 macro-
phages, which is mediated by IL-17 as anti–IL-17 neutralizing 
antibodies inhibit IL-17–mediated induction of macrophage 
migration. However, our data show that lung tumors express 
higher levels of COX-2 compared with normal lung tissues, 
leading to higher levels of PGE2 in the lung tumors. PGE2 
induces expression of arginase I and IL-10, markers of M2 
macrophages, in RAW264.7 macrophages. Taken together, 
our data suggest that, in the lung tumor microenvironment, 
monocytes/macrophages are recruited by chemoattractant 
IL-17, and subsequently PGE2 induces their differentiation 
into M2 macrophages (Fig. 4F). Thus, IL-17 and PGE2 con-
tribute to the creation of an M2-macrophage–dominant tumor 
microenvironment in lung cancer.13
It is worth pointing out that IL-17 and PGE2 are not 
the only factors that can affect the tumor microenvironment. 
Lung tumors express other chemokines and cytokines such as 
IL-8 and colony-stimulating factor1, which can recruit macro-
phages.32 IL-4, IL-10, TNFα, and INF-γ are also expressed in 
lung tumors.32 IL-4 and IL-10 can induce M2-macrophage dif-
ferentiation and TNFα and INF-γ can induce M1-macrophage 
differentiation.5–9 Thus, monocytes/macrophages are exposed 
to complex signals that induce them to differentiate into either 
M1 or M2 macrophages (Fig. 4F). On the basis of our pre-
vious finding that 70% of TAMs are M2 macrophages,13 we 
speculate that the signals for M2-macrophage differentiation 
dominate the lung tumor microenvironment. This is supported 
by our data showing that M2-macrophage markers (arginase I 
and IL-10) are increased by 4000- to 6000-fold in RAW264.7 
macrophages when the macrophages are cocultured with 
human lung cancer cells, whereas M1-macrophage markers 
are induced by a maximum of sixfold. Other investigators 
have also found that arginase I expression in mouse perito-
neal macrophages is induced by coculture with murine Lewis 
lung carcinoma cells.28 Of note, the conditioned medium of 
A549 cells is less effective in induction of arginase I and 
IL-10 in RAW264.7 macrophages than coculture of A549 
cells with RAW264.7 macrophages, suggesting that there may 
be some paracrine factors and/or direct intercellular interac-
tions involved in macrophage differentiation in lung tumor 
microenvironment. Our data show that the boiled condi-
tioned medium is more effective than the native conditioned 
medium, indicating that some counteracting heat-labile fac-
tors are deactivated during boiling, thus enhancing the effects 
of heat-stable factors such as PGE2. However, pure PGE2 
seems to be less effective in the induction of arginase I and 
IL-10 than the boiled conditioned medium, suggesting a pos-
sibility that other heat-stable factors may exist in the condi-
tioned medium. It has been reported that PGE2 can induce 
differentiation of myeloid-derived suppressor cells from bone-
marrow stem cells,33 and IL-10 secreted by myeloid-derived 
suppressor cells can skew macrophages toward an M2 phe-
notype.34 Thus, PGE2 may induce M2-macrophage differen-
tiation through direct and indirect mechanisms in the in vivo 
tumor microenvironment.
In summary, the present study provides evidence 
that IL-17 and PGE2 contribute to the formation of an 
M2-macrophage–dominant tumor microenvironment in lung 
cancer. Because M2 macrophages are believed to promote 
tumor growth and metastasis, IL-17 and PGE2 might be 
potential therapeutic targets in the treatment of lung cancer.
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